

Intellicell Biosciences, Inc.  
Form NT 10-K  
March 30, 2012

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 12b-25

Commission File Number 333-49388  
CUSIP Number 45825A 105

NOTIFICATION OF LATE FILING

<input checked="" type="checkbox"/> Form 10-K	<input type="checkbox"/> Form 11-K	<input type="checkbox"/> Form 20-F	<input type="checkbox"/> Form 10-Q
<input type="checkbox"/> Form N-SAR			

For Period Ended: December 31, 2011

Transition Report on Form 10-K  
 Transition Report on Form 20-F

Transition Report on Form 10-Q  
 Transition Report on Form N-SAR

For the Transition Period Ended: \_\_\_\_\_

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

\_\_\_\_\_  
\_\_\_\_\_

PART I  
REGISTRANT INFORMATION

Full name of registrant	Intellicell Biosciences, Inc.
Address of principal executive office	30 East 76th Street, 6th Floor,
City, state and zip code	New York, New York 10021

PART II  
RULE 12b-25 (b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate)

- T
- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
  - (b) The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form 10-Q, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
  - (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III  
NARRATIVE

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period.

The compilation, dissemination and review of the information required to be presented in the Annual Report on Form 10-K for the relevant period has imposed time constraints that have rendered timely filing of the Annual Report on Form 10-K impracticable without undue hardship and expense to the registrant. The registrant undertakes the responsibility to file such report no later than fifteen days after its original prescribed due date.

PART IV  
OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Steven A Victor, MD, Chief Executive Officer, (212) 249-3050

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

T Yes    .. No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

T Yes    .. No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

On June 3, 2011, the registrant acquired Intellicell Biosciences, Inc., a New York corporation ("Intellicell"), in a transaction which was accounted for as a reverse acquisition. As a result, the results of operations for periods prior to June 3, 2011, will be the results of operations of Intellicell, which is the accounting acquirer.



Intellicell Biosciences, Inc.  
Name of Registrant as Specified in Charter.

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: March 30, 2012

By: /s/ Steven A. Victor  
Name: Steven A. Victor  
Title Title: Chief Executive Officer